[SEOUL, South Korea, November 14, 2023] Bionet has successfully obtained FDA clearance for Cardio P1, a PC-based ECG system.
Cardio P1, a compact ECG designed to interface with a PC, offers a user-friendly experience by seamlessly integrating with ‘CardioSync,’ a dedicated software program for PCs. It streamlines the workflow from patient registration to examination, ensuring a quick and straightforward process for users.This product not only prioritizes ease of use but also stands out for its precision algorithms in ECG reading, enabling accurate and swift diagnosis of abnormal heart rhythms. Additionally, it features a full disclosure function capable of storing and displaying ECG data for up to 30 minutes. This functionality allows healthcare professionals to delve deeper into ECG results, ensuring no small details are overlooked. Furthermore, Cardio P1 facilitates real-time ECG measurements while concurrently providing diagnostic results. It can instantly diagnose 13 types of arrhythmias during the test and offer 120 diagnoses post-test.
The FDA clearance stands as a testament to the high accuracy and usability of Cardio P1. This recognition is anticipated to fortify the product’s reliability and elevate its competitiveness in the global market. We remain dedicated to strengthening our sales and marketing initiatives, highlighting the acknowledged performance of Cardio P1 by the FDA.